Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors
Conditions
Brief summary
AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly specific inhibitor of the KIT gene, in CBF-AML with KIT mutations.
Detailed description
Acute Myeloid Leukemia (AML) with the chromosomal abnormality of t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as the Core Binding Factor AML (CBF-AML). KIT mutation is a common mutation in CBF-AML, which is more likely to relapse and have a worse prognosis. Avapritinib is an oral tyrosine kinase inhibitor (TKI) with selective inhibitory activity against KIT and PDGFRA. Avapritinib has been approved by FDA for the treatment of gastrointestinal stromal tumors(GIST) with PDGFRA mutations and Advanced systemic mastocytosis (AdvSM). However, the efficacy of avapritinib in AML with KIT mutations is uncertain. This prospective, multicenter clinical study of the efficacy and safety of avapritinib in relapsed refractory or molecular minimal residual disease (MRD)-positive AML with KIT mutations.
Interventions
DRUGAvapritinib
administered orally
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with acute myeloid leukemia accompanied by t(8; 21)/RUNX1-RUNX1T1, or inv(16)/t(16; 16)/CBFβ-MYH11; 2. Accompanied by KIT mutation 3. Disease recurrence after the first remission, or the mol-MRD remains positive after the morphologic remission of AML. 4. No active infection. 5. Liver function: TBIL≤ 2×ULN,ALT/AST≤ 3×ULN, CCr ≥ 50ml/min，NYHA grading ≤2; SaO2 \>92%. 6. ECOG \<2; (11) Predicted survival \> 12 weeks.
Exclusion criteria
1. Accept other AML targeted therapies, such as dasatinib, sorafenib, gilteritinib, etc. simultaneously; 2. The presence of uncontrolled and active infections (including bacterial, fungal or viral infections). 3. Underlying diseases such as myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal failure, etc. 4. Pregnant or lactating women; 5. Accompanied by other malignant tumors requiring treatment; 6. Other interventional clinical studies have been enrolled.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite complete remission (CRc) | Assessed at protocol-defined timepoints through end of study, up to approximately 36 months. | The proportion of participants who achieve Composite complete remission (CRc)，which includes complete remission (CR)、CR with partial hematologic recovery (CRh)、CR with incomplete blood count recovery (CRi) and morphology leukemia free (MLFS) based on response criteria for AML. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MRD-negative rate | Assessed at protocol-defined timepoints through end of study, up to approximately 36 months. | The proportion of participants who achieve a negative molecular MRD. |
| Progression-free survival (PFS) | From the first day of treatment until any failure (resistant disease, relapse, or death), assessed up to 1 to 3 years. | The Kaplan-Meier method will be used to assess PFS probabilities. |
| Overall survival (OS) | From the first day of treatment to time of death from any cause, assessed up 1 to 3 years. | The Kaplan-Meier method will be used to assess OS probabilities. |
| Incidence of adverse events (AEs) | Up to approximately 1 to 3 years. | Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. The proportion of patients with AEs will be estimated, along with the 95% credible interval. |
Countries
China
Contacts
Primary ContactSuning Chen
Backup ContactHaiping Dai
Outcome results
None listed